Enrichment of potent GSK-3 β inhibitors from docking studies in the enzyme active site

Current Science

Volumn 93, Issue 8, 2007, Pages 1100-1107

  Gadakar, Pravin Kumar ^a   Phukan, Samiron ^a   Dattatreya, Prasanna M ^a   Balaji, V N ^a  

^a JUBILANT BIOSYS LTD   (India)

Author keywords

Database; Enrichment; Glycogen synthase kinase 3 ; Induced fit docking; Molecular docking studies

Indexed keywords

EID: 36148970836     PISSN: 00113891     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Frame, S., Cohen, P. and Biondi, R. M., A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol. Cell, 2001, 7, 1321-1327.
2. Mukai, F., Ishiguro, K., Sano, Y. and Fujita, S. C., Alternative splicing isoform of tau protein kinase I/glycogen synthase kinase 3 β. J. Neurochem., 2002, 81, 1073-1083.
3. Doble, B. W. and Woodgett, J. R., GSK-3: Tricks of the trade for a multi-tasking kinase. J. Cell Sci., 2003, 116, 1175-1186.
4. McManus, E. J., Sakamoto, K., Armit, L. J., Ronaldson, L., Shapiro, N., Marquez, R. and Alessi, D. R., Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis. EMBO J., 2005, 24, 1571-1583.
5. Wagman, A. S., Johnson, K. W. and Bussiere, D. E., Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes. Curr. Pharm. Des., 2004, 10, 1105-1137.
6. Li, L. et al., Axin and Frat1 interact with Dvl and GSK, bridging Dvl to GSK in Wnt-mediated regulation of LEF-1. EMBO J., 1999, 18, 4233-4240.
7. Bhat, R. V. and Budd, S. L., GSK3 β signalling: Casting a wide net in Alzheimer's disease. Neurosignals, 2002, 11, 251-261.
8. Bax B. et al., The structure of phosphorylated GSK-3 β Complexed with a Peptide, FRATtide, that inhibits β-catenin Phosphorylation. Structure, 2001, 9, 1143-1152.
9. Dajani, R., Fraser, E., Roe, S. M., Young, N., Good, V., Dale, T. C. and Pearl, L. H., Crystal structure of glycogen synthase kinase 3 β: Structural basis for phosphate-primed substrate specificity and autoinhibition. Cell, 2001, 105, 721-732.
10. Ter Haar, E., Coll J. T., Austen D. A., Hsiao, H. M., Swenson, L. and Jain, J., Structure of GSK3 β reveals a primed phosphorylation mechanism. Nature Struct. Biol., 2001, 8, 593-596.
11. Dajani, R., Fraser, E., Roe, S. M., Yeo, M. and Good. V. M. and Thompson. V., Structural basis for recruitment of glycogen synthase kinase 3 β to the axin-APC scaffold complex. EMBO J., 2003, 22, 494-501.
12. Bertrand, J. A. et al., Structural characterization of the Gsk-3 β active site using selective and non-selective ATP-mimetic inhibitors. J. Mol. Biol., 2003, 333, 393-407.
13. Bhat, R. et al., Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor Ar-A014418. J. Biol. Chem., 2003, 278, 45937-45945.
14. Meijer, L. et al., Gsk-3-selective inhibitors derived from Tyrian purple indurubins. Chem. Biol., 2003, 10, 1255.
15. Bussiere, D. E., He M., Le, V. P., Jansen J. M., Chin, S. M. and Martin, E., Crystallization and crystal structure of human glycogen synthase kinase 3 β protein and methods of use thereof. Chiron Corporation, USA, International Application No. WO 0224893, 2002.
16. Aoki, M. et al., Structural insight into nucleotide recognition in tau-protein kinase I/glycogen synthase kinase 3 beta. Acta Crystallogr. Sect. D, 2004, 60, 439-446.
17. Berman, H. M. et al., The protein data bank. Nucleic Acids Res., 2000, 28, 235-242.
18. Lescot, E., Bureau, R., de Oliveira Santos, J. S., Rochais, C., Lisowski, V., Lancelot, J. C. and Rault, S., 3D-QSAR and docking studies of selective GSK-3 β inhibitors. comparison with a thieno[2,3-b]pyrrolizinone derivative, a new potential lead for GSK-3 β ligands. J. Chem. Inf. Model., 2005, 45, 708-715.
19. Maestro (v7.0.113) - A unified interface for all Schrodinger products, developed and marketed by Schrodinger, LLC. NY, Copyright 2005; http://www.schrodinger.com
20. Halgren, T. A., Merck molecular force field. I. Basis, form, scope, parameterization and performance of MMFF94. J. Comput. Chem., 1996, 17, 490-519;
21. Halgren, T. A., Merck molecular force field. II. MMFF94 van der Waals and electrostatic parameters for intermolecular interactions. J. Comput. Chem., 1996, 17, 520-552;
22. Halgren, T. A., Merck molecular force field. III. Molecular geometrics and vibrational frequencies for MMFF94. J. Comput. Chem., 1996, 17, 553-586;
23. Halgren, T. A. and Nachbar, R. B., Merck molecular force field. IV. Conformational energies and geometries. J. Comput. Chem., 1996, 17, 587-615;
24. Halgren, T. A., Merck molecular force field. V. Extension of MMFF94 using experimental data, additional computational data and empirical rules. J. Comput. Chem., 1996, 17, 616-641;
25. Halgren, T. A., MMFF VI. MMFF94s option for energy minimization studies. J. Comput. Chem., 1999, 20, 720-729;
26. Halgren, T. A., MMFF VII. Characterization of MMFF94, MMFF94s and other widely available force fields for conformational energies and for intermolecular interaction energies and geometries. J. Comput. Chem., 1999, 20, 730-748.
27. Rizzo, R. C. and Jorgensen, W. L., J. Am. Chem. Soc., 1999, 121, 4827-4836;
28. Jacobson, M. P., Kaminski, G. A., Friesner, R. A. and Rapp, C. S., Force field validation using protein side chain prediction. J. Phys. Chem. B., 2002, 106, 11673-11680.
29. Friesner, R. A. et al., Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem., 2004, 47, 1739-1749.
30. Halgren, T. A., Murphy, R. B., Friesner, R. A., Beard, H. S., Frye, L. L. Pollard, W. T. and Banks, J. L., Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J. Med. Chem., 2004, 47, 1750-1759.
31. Sherman, B., Day, T., Jacobson, M. P., Friesner, R. A. and Farid, R. A., Novel procedure for modeling ligand/receptor induced fit effects. J. Med. Chem., 2006, 49, 534-553.
32. Friesner, R. A. et al., ExtraPrecision glide - Docking and scoring based on a new theory of molecular recognition. J. Med. Chem., 2006, 49, 6177-6199.